We Address Unmet Medical Needs to Improve Patient Outcomes and Quality of Life
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi® and Submits Market Authorization Application in Switzerland
The product portfolio is led by already commercialized Binosto® for the treatment of postmenopausal osteoporosis.
Partnering with Us
Our strategy relies on partnerships for shared commercial success. We welcome you to find out more about partnering.